Transgene SA

Symbol: 0OCQ.L

LSE

1.248

EUR

Market price today

  • -3.7467

    P/E Ratio

  • -2.5478

    PEG Ratio

  • 135.28M

    MRK Cap

  • 0.00%

    DIV Yield

Transgene SA (0OCQ-L) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

-4.76%

Operating Profit Margin

-9.82%

Net Profit Margin

-6.52%

Return on Assets

-0.74%

Return on Equity

-1.78%

Return on Capital Employed

-1.43%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO:Dr. Alessandro Riva M.D.
Full-time employees:141
City:Illkirch-Graffenstaden
Address:400, Boulevard Gonthier d’Andernach
IPO:2008-11-05
CIK:

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

General Outlook

When we look at how much money they make before expenses, they keep -4.763% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -9.816%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -6.524%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.741% return, is a testament to Transgene SA's adeptness in optimizing resource deployment. Transgene SA's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.783%. Furthermore, the proficiency of Transgene SA in capital utilization is underscored by a remarkable -1.433% return on capital employed.

Stock Prices

Transgene SA's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.05, while its low point bottomed out at $1.05. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Transgene SA's stock market.

Liquidity Ratios

Analyzing 0OCQ.L liquidity ratios reveals its financial health of the firm. The current ratio of 179.09% gauges short-term asset coverage for liabilities. The quick ratio (170.55%) assesses immediate liquidity, while the cash ratio (156.00%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio179.09%
Quick Ratio170.55%
Cash Ratio156.00%

Profitability Ratios

0OCQ.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -777.99% underscores its earnings before tax deductions. The effective tax rate stands at 16.15%, revealing its tax efficiency. The net income per EBT, 83.85%, and the EBT per EBIT, 79.25%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -981.63%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-777.99%
Effective Tax Rate16.15%
Net Income per EBT83.85%
EBT per EBIT79.25%
EBIT per Revenue-981.63%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.79, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 2 cash conversion cycle and 351.40% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding171
Operating Cycle103.87
Days of Payables Outstanding56
Cash Conversion Cycle48
Receivables Turnover3.51
Payables Turnover6.51
Fixed Asset Turnover0.42
Asset Turnover0.11

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.52, and free cash flow per share, -0.56, depict cash generation on a per-share basis. The cash per share value, 0.16, showcases liquidity position. Lastly, the operating cash flow sales ratio, -10.19, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.52
Free Cash Flow per Share-0.56
Cash per Share0.16
Operating Cash Flow Sales Ratio-10.19
Free Cash Flow to Operating Cash Flow Ratio1.08
Cash Flow Coverage Ratio-3.04
Short Term Coverage Ratio-42.18
Capital Expenditure Coverage Ratio-12.82
Dividend Paid and Capex Coverage Ratio-12.82

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 38.05%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.10, we discern the balance between debt and equity financing. The long-term debt to capitalization, 50.56%, and total debt to capitalization, 52.42%, ratios shed light on its capital structure. An interest coverage of -1292.23 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio38.05%
Debt Equity Ratio1.10
Long Term Debt to Capitalization50.56%
Total Debt to Capitalization52.42%
Interest Coverage-1292.23
Cash Flow to Debt Ratio-3.04
Company Equity Multiplier2.90

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.01, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.22, reflects the portion of profit attributed to each share. The book value per share, 0.16, represents the net asset value distributed per share, while the tangible book value per share, 0.19, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.01
Net Income Per Share-0.22
Book Value Per Share0.16
Tangible Book Value Per Share0.19
Shareholders Equity Per Share0.16
Interest Debt Per Share0.17
Capex Per Share-0.03

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -62.12%, indicates top-line expansion, while the gross profit growth, 2.20%, reveals profitability trends. EBIT growth, 4.23%, and operating income growth, 4.23%, offer insights into operational profitability progression. The net income growth, 31.94%, showcases bottom-line expansion, and the EPS growth, 33.33%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-62.12%
Gross Profit Growth2.20%
EBIT Growth4.23%
Operating Income Growth4.23%
Net Income Growth31.94%
EPS Growth33.33%
EPS Diluted Growth33.33%
Weighted Average Shares Growth1.09%
Weighted Average Shares Diluted Growth1.09%
Operating Cash Flow Growth-66.92%
Free Cash Flow Growth-67.74%
10-Year Revenue Growth per Share-97.62%
5-Year Revenue Growth per Share-89.74%
3-Year Revenue Growth per Share-66.97%
10-Year Operating CF Growth per Share77.92%
5-Year Operating CF Growth per Share23.49%
3-Year Operating CF Growth per Share-0.74%
10-Year Net Income Growth per Share83.49%
5-Year Net Income Growth per Share-270.75%
3-Year Net Income Growth per Share-7.75%
10-Year Shareholders Equity Growth per Share-91.26%
5-Year Shareholders Equity Growth per Share-73.88%
3-Year Shareholders Equity Growth per Share-74.16%
Receivables Growth-60.24%
Asset Growth-31.94%
Book Value per Share Growth-59.19%
Debt Growth-48.67%
R&D Expense Growth-8.17%
SGA Expenses Growth-11.73%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 123,399,104.09, captures the company's total value, considering both debt and equity. Income quality, 1.57, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 5.90, gauges operational efficiency, while the research and development to revenue, 2369.93%, highlights investment in innovation. The ratio of intangibles to total assets, 0.18%, indicates the value of non-physical assets, and capex to operating cash flow, 7.85%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value123,399,104.09
Income Quality1.57
Sales General and Administrative to Revenue5.90
Research and Development to Revenue2369.93%
Intangibles to Total Assets0.18%
Capex to Operating Cash Flow7.85%
Capex to Revenue-231.93%
Capex to Depreciation-173.14%
Stock-Based Compensation to Revenue24.49%
Graham Number0.88
Return on Tangible Assets-49.47%
Graham Net Net-0.10
Working Capital7,942,000
Tangible Asset Value18,620,000
Net Current Asset Value-8,533,000
Invested Capital1
Average Receivables2,568,000
Average Payables5,755,000
Days Sales Outstanding450
Days Payables Outstanding56
ROIC-83.68%
ROE-1.43%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 8.04, and the price to book ratio, 8.04, reflect the market's valuation relative to the company's book value. The price to sales ratio, 26.35, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -2.40, and price to operating cash flows, -2.40, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio8.04
Price to Book Ratio8.04
Price to Sales Ratio26.35
Price Cash Flow Ratio-2.40
Price Earnings to Growth Ratio-2.55
Enterprise Value Multiple-3.12
Price Fair Value8.04
Price to Operating Cash Flow Ratio-2.40
Price to Free Cash Flows Ratio-2.40
Price to Tangible Book Ratio8.83
Enterprise Value to Sales104.22
Enterprise Value Over EBITDA-3.65
EV to Operating Cash Flow-3.53
Earnings Yield-16.20%
Free Cash Flow Yield-27.37%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Transgene SA (0OCQ.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.747 in 2024.

What is the ticker symbol of Transgene SA stock?

The ticker symbol of Transgene SA stock is 0OCQ.L.

What is company IPO date?

IPO date of Transgene SA is 2008-11-05.

What is company current share price?

Current share price is 1.248 EUR.

What is stock market cap today?

The market cap of stock today is 135284007.000.

What is PEG ratio in 2024?

The current -2.548 is -2.548 in 2024.

What is the number of employees in 2024?

In 2024 the company has 141.